IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine
by Zacks Equity Research
Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line.
Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care
by Zacks Equity Research
Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Cardinal Health (CAH) Inks Deal to Divest Cordis Business
by Zacks Equity Research
Cardinal Health (CAH) divests its Cordis business to focus on strategic growth areas.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about robust demand for Hill-Rom's (HRC) product as well as its solid first-quarter fiscal 2021 results.
IDEXX Laboratories (IDXX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
IDEXX Laboratories (IDXX) has been struggling lately, but the selling pressure may be coming to an end soon
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.
PerkinElmer (PKI) Boosts Testing Portfolio With New Solutions
by Zacks Equity Research
PerkinElmer's (PKI) introduction of two comprehensive solutions is likely to strengthen its COVID-19 testing portfolio further.
BD (BDX), ImageMover Partner for Rapid Antigen Test Reporting
by Zacks Equity Research
BD (BDX) collaborates with ImageMover to streamline rapid antigen testing results performed on the BD Veritor Plus System.
Hologic (HOLX) Partners With Gallup on Women's Health Index
by Zacks Equity Research
Hologic (HOLX) is working to develop a global women's health index through Gallup's World Poll to improve quality of life and life expectancy of women worldwide.
Abbott (ABT) Launches Telehealth Tool for Neuromodulation
by Zacks Equity Research
Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.
QIAGEN (QGEN) Rides on Test Launches Amid COVID-19 Woes
by Zacks Equity Research
QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.
Myriad Genetics (MYGN) Collaborates to Advance Oncology Care
by Zacks Equity Research
Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.
Why Is Idexx (IDXX) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q4.
Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF
by Zacks Equity Research
Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Hologic (HOLX) Boosts Diagnostics Portfolio With New Buyout
by Zacks Equity Research
Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.
Here's Why You Should Add Abbott (ABT) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) due to a slew of product launches and regulatory approvals.
Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines
by Zacks Equity Research
Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.